What is Oncolytics Biotech?
Oncolytics Biotech Inc. is a development-stage biopharmaceutical firm dedicated to the discovery and advancement of pharmaceutical products for cancer treatment. The company's lead candidate, REOLYSIN, is an immuno-oncology viral agent designed to trigger selective tumor lysis and modulate immune responses. REOLYSIN is being explored across three distinct programs: combinations with chemotherapy to enhance tumor cell death, combinations with immune modulators to stimulate innate immune responses, and combinations with immunotherapies to foster adaptive immune responses. Founded in 1998 and headquartered in Alberta, Canada, Oncolytics Biotech is strategically positioned to address unmet needs in oncology through its innovative viral-based therapeutic approach.
How much funding has Oncolytics Biotech raised?
Oncolytics Biotech has raised a total of $15M across 1 funding round:
Share Placement
$15M
Share Placement (2023): $15M with participation from Leede Jones Gable
Key Investors in Oncolytics Biotech
Leede Jones Gable
Leede Jones Gable is an independent, employee-owned financial firm offering investment, portfolio management, and insurance services. Their involvement suggests a strategic financial backing for Oncolytics Biotech's development stage.
What's next for Oncolytics Biotech?
The recent major strategic investment signals a pivotal phase for Oncolytics Biotech, likely enabling the acceleration of its clinical development pipeline for REOLYSIN. This enterprise-level funding is expected to support the progression of its various combination therapy programs, potentially moving them closer to commercialization. The company's focus on immuno-oncology aligns with current trends in cancer treatment, suggesting a strategic direction aimed at leveraging the body's own immune system to combat malignancies. Future developments will likely center on clinical trial outcomes and potential partnerships to further validate and scale its therapeutic offerings.
See full Oncolytics Biotech company page
